ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2016
Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.Epidemiology (Cambridge, Mass.) · 2020Pooled it
- Trial
- Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children.Clinical and experimental immunology · 2020Trial
- Intraseasonal waning of influenza vaccine effectiveness and implications for the optimal timing of seasonal vaccination programs: A scoping review.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- Epidemiological Impact of the Pediatric Live Attenuated Influenza Vaccine (LAIV) Program on Group AOpen forum infectious diseases · 2023Article
- Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
- How the COVID 19 pandemic will shape influenza public health initiatives: The UK experience.Human vaccines & immunotherapeutics · 2022Article
- The impact of repeated vaccination on relative influenza vaccine effectiveness among vaccinated adults in the United Kingdom.Epidemiology and infection · 2022Article
- Roles for Pathogen Interference in Influenza Vaccination, with Implications to Vaccine Effectiveness (VE) and Attribution of Influenza Deaths.Infectious disease reports · 2022Review
- Live-attenuated influenza vaccine effectiveness against hospitalization in children aged 2-6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14-2015/16.Influenza and other respiratory viruses · 2022Article
- Live Attenuated Cold-Adapted Influenza Vaccines.Cold Spring Harbor perspectives in medicine · 2021Review
- [Health Technology Assessment (HTA) of the introduction of influenza vaccination for Italian children with Fluenz TetraJournal of preventive medicine and hygiene · 2021Article
- Global Ethical Considerations Regarding Mandatory Vaccination in Children.The Journal of pediatrics · 2021Article
- Decline in Seasonal Influenza Vaccine Effectiveness With Vaccination Program Maturation: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2021Article
- Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.Health technology assessment (Winchester, England) · 2020Article
- COVID-19 Surveillance in a Primary Care Sentinel Network: In-Pandemic Development of an Application Ontology.JMIR public health and surveillance · 2020Article
- Optimising age coverage of seasonal influenza vaccination in England: A mathematical and health economic evaluation.PLoS computational biology · 2020Article
- Variations in Seasonal Influenza Vaccine Effectiveness due to Study Characteristics: A Systematic Review and Meta-analysis of Test-Negative Design Studies.Open forum infectious diseases · 2020Review
- Viral Shedding in Recipients of Live Attenuated Influenza Vaccine in the 2016-2017 and 2017-2018 Influenza Seasons in the United Kingdom.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Successes and Failures of the Live-attenuated Influenza Vaccine: Can We Do Better?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The United Kingdom (UK) is in the third season of introducing universal paediatric influenza vaccination with a quadrivalent live attenuated influenza vaccine (LAIV). The 2015/16 season in the UK was initially dominated by influenza A(H1N1)pdm09 and then influenza of B/Victoria lineage, not contained in that season's adult trivalent inactivated influenza vaccine (IIV). Overall adjusted end-of-season vaccine effectiveness (VE) was 52.4% (95% confidence interval (CI): 41.0-61.6) against influenza-confirmed primary care consultation, 54.5% (95% CI: 41.6-64.5) against influenza A(H1N1)pdm09 and 54.2% (95% CI: 33.1-68.6) against influenza B. In 2-17 year-olds, adjusted VE for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any influenza, 81.4% (95% CI: 39.6-94.3) against influenza B and 41.5% (95% CI: -8.5 to 68.5) against influenza A(H1N1)pdm09. These estimates demonstrate moderate to good levels of protection, particularly against influenza B in children, but relatively less against influenza A(H1N1)pdm09. Despite lineage mismatch in the trivalent IIV, adults younger than 65 years were still protected against influenza B. These results provide reassurance for the UK to continue its influenza immunisation programme planned for 2016/17.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.